Needham Maintains Bicycle Therapeutics(BCYC.US) With Buy Rating, Maintains Target Price $30

Moomoo NewsMar 11 13:31 ET · Ratings

Promising Upside for Bicycle Therapeutics: Buy Rating Backed by Positive Clinical Data and Market Potential for ZP Treatment

TipRanksMar 11 09:45 ET · Ratings

Bicycle Therapeutics Grants 73,700 Share Options To Eight New Employees Under 2024 Inducement Plan

BenzingaMar 5 07:14 ET

Bicycle Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

BusinesswireMar 5 07:00 ET

Companies Like Bicycle Therapeutics (NASDAQ:BCYC) Are In A Position To Invest In Growth

Simply Wall StFeb 28 06:43 ET

Eckert & Ziegler Enters Strategic Partnership With Bicycle Therapeutics For Radioisotope Supply And Contract Development And Manufacturing Of Bicycle Radio Conjugates

BenzingaFeb 27 09:08 ET